Valuation: Alterity Therapeutics Limited

Market Cap 101M 88.35M 81.2M 75.69M 144M 9.62B 146M 975M 379M 4.73B 379M 371M 16.3B P/E 2026 *
-0.39x
P/E 2027 * -0.39x
Enterprise Value 55.88M 48.85M 44.89M 41.85M 79.37M 5.32B 80.57M 539M 210M 2.62B 210M 205M 9.01B EV / Sales 2026 *
21.8x
EV / Sales 2027 * 50.1x
Free-Float
91.47%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Alterity Therapeutics Limited

1 day+450.00%
6 months-82.40%
Current year-82.40%
Current year 0.01
Extreme 0.01
0.54
1 year 0.01
Extreme 0.01
0.54
3 years 0.01
Extreme 0.01
0.7
5 years 0.01
Extreme 0.01
2.36
10 years 0
Extreme 0.005
4.75
Manager TitleAgeSince
Chief Executive Officer 65 07/01/2021
Director of Finance/CFO - 30/09/2024
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 70 29/07/2005
Director/Board Member 47 08/08/2011
Director/Board Member 65 21/11/2025
Change 5-day change 1-year change 3-year change Capi.($)
+450.00%-.--% - - 98.01M
+1.70%+7.41%+3.12%+8.46% 49.15B
+0.92%+6.21%+408.85%+607.44% 40.23B
+1.89%+11.06%+25.75%-7.89% 34.55B
+5.46%+8.10%+21.83%+66.94% 33.09B
+3.96%+6.07%+14.14%+37.68% 25.19B
+2.51%+4.94% - - 17.05B
+2.58%+7.24%+71.03%+132.17% 15.92B
+0.32%+0.58%+13.67%+19.09% 13.83B
-1.14%+7.52%+14.75%-30.83% 13.26B
Average +46.48%+5.99%+71.64%+104.13% 26.92B
Weighted average by Cap. +1.92%+6.31%+89.18%+131.90%

Financials

2026 *2027 *
Net sales 2.57M 2.25M 2.06M 1.92M 3.65M 245M 3.7M 24.77M 9.63M 120M 9.64M 9.43M 414M 1.2M 1.05M 964K 899K 1.7M 114M 1.73M 11.58M 4.5M 56.18M 4.51M 4.41M 194M
Net income -14.62M -12.78M -11.75M -10.95M -20.77M -1.39B -21.08M -141M -54.83M -684M -54.89M -53.71M -2.36B -29.6M -25.88M -23.78M -22.17M -42.05M -2.82B -42.68M -286M -111M -1.39B -111M -109M -4.77B
Net Debt -45.19M -39.5M -36.3M -33.84M -64.18M -4.3B -65.16M -436M -169M -2.11B -170M -166M -7.29B -40.88M -35.74M -32.84M -30.61M -58.07M -3.89B -58.95M -394M -153M -1.91B -153M -150M -6.59B
Logo Alterity Therapeutics Limited
Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. Its lead asset, ATH434, is in a randomized, double blind, placebo-controlled Phase II clinical trial in participants with MSA. The Company is also conducting various nonclinical studies with ATH434 for use in Parkinson’s disease based on imaging of brain iron, preservation of neurons, and improvements in motor performance.
Employees
9
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.6700AUD
Average target price
2.280AUD
Spread / Average Target
+240.30%

Quarterly revenue - Rate of surprise